Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation With DOJ
Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
You may also be interested in...
How DOJ Built Its Generic Price Fixing Case: Cooperating Witnesses At Competitors
Former sales and marketing exec at Taro Pharmaceuticals is latest exec charged with participating in price fixing conspiracies.
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
Generic Price Fixing Litigation Presses On With 'Overarching Conspiracy' Claims Intact
Judge allows plaintiffs to argue attendance at trade association meetings and job-hopping show scheme to fix drug prices; confidentiality of attorney communication is in dispute.